Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Intrinsic Value
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. [ Read More ]
The intrinsic value of one ARWR stock under the Base Case scenario is 35.05 USD. Compared to the current market price of 28.6 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 18%.
Valuation Backtest
Arrowhead Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling ARWR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Arrowhead's Year of Expansion and R&D Growth
2024-Q1 Earnings Call
Arrowhead reported a significant increase in net loss for the quarter ended December 31, 2023, to $132.9 million, up from $41.3 million in the same period the prior year. Revenue was down to $3.6 million from $62.5 million, owing largely to the full recognition of upfront payments from past agreements. Operating expenses rose to $140.1 million due to more advanced clinical candidate development. The quarterly cash burn is projected at $80 to $100 million with nominal future capital expenditures. Key developments include expected Phase 3 results and NDA filing for Plozasiran, multiple clinical readouts, a structured finance initiative, continued collaboration with Takeda and Amgen, and an upcoming adipose-targeted clinical candidate.
Balance Sheet Decomposition
Arrowhead Pharmaceuticals Inc
Current Assets | 237.9m |
Cash & Short-Term Investments | 220.3m |
Other Current Assets | 17.6m |
Non-Current Assets | 388.4m |
PP&E | 378.3m |
Intangibles | 9.8m |
Other Non-Current Assets | 232k |
Current Liabilities | 63.7m |
Accounts Payable | 4.5m |
Accrued Liabilities | 58.8m |
Other Current Liabilities | 461k |
Non-Current Liabilities | 402.2m |
Other Non-Current Liabilities | 402.2m |
Earnings Waterfall
Arrowhead Pharmaceuticals Inc
Revenue
|
181.7m
USD
|
Operating Expenses
|
-481.1m
USD
|
Operating Income
|
-299.4m
USD
|
Other Expenses
|
2.6m
USD
|
Net Income
|
-296.7m
USD
|
Free Cash Flow Analysis
Arrowhead Pharmaceuticals Inc
What is Free Cash Flow?
ARWR Profitability Score
Profitability Due Diligence
Arrowhead Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Arrowhead Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
ARWR Solvency Score
Solvency Due Diligence
Arrowhead Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Arrowhead Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARWR Price Targets Summary
Arrowhead Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ARWR is 56.49 USD with a low forecast of 28.28 USD and a high forecast of 94.5 USD.
Ownership
ARWR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ARWR Price
Arrowhead Pharmaceuticals Inc
Average Annual Return | 52.77% |
Standard Deviation of Annual Returns | 130.12% |
Max Drawdown | -77% |
Market Capitalization | 3.5B USD |
Shares Outstanding | 123 897 000 |
Percentage of Shares Shorted | 8.37% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 329 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The firm's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.
Contact
IPO
Employees
Officers
The intrinsic value of one ARWR stock under the Base Case scenario is 35.05 USD.
Compared to the current market price of 28.6 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 18%.